Join Growin Stock Community!

China pharma holdings, inc.CPHI.US Overview

US StockHealthcare
(No presentation for CPHI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CPHI AI Insights

CPHI Overall Performance

CPHI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CPHI Recent Performance

-0.96%

China pharma holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CPHI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CPHI Key Information

CPHI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CPHI Profile

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

Price of CPHI

CPHI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CPHI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.71
PB Ratio
0.35
Price-to-FCF
11.54
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-10.94%
Net Margin
-78.72%
Revenue Growth (YoY)
-26.92%
Profit Growth (YoY)
76.72%
3-Year Revenue Growth
-27.27%
3-Year Profit Growth
-80.40%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.71
PB Ratio
0.35
Price-to-FCF
11.54
Gross Margin
-10.94%
Net Margin
-78.72%
Revenue Growth (YoY)
-26.92%
Profit Growth (YoY)
76.72%
3-Year Revenue Growth
-27.27%
3-Year Profit Growth
-80.40%

  • When is CPHI's latest earnings report released?

    The most recent financial report for China pharma holdings, inc. (CPHI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CPHI's short-term business performance and financial health. For the latest updates on CPHI's earnings releases, visit this page regularly.

  • What is the operating profit of CPHI?

    According to the latest financial report, China pharma holdings, inc. (CPHI) reported an Operating Profit of -628.15K with an Operating Margin of -83.06% this period, representing a growth of 42.12% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CPHI's revenue growth?

    In the latest financial report, China pharma holdings, inc. (CPHI) announced revenue of 756.22K, with a Year-Over-Year growth rate of -31.26%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CPHI have?

    As of the end of the reporting period, China pharma holdings, inc. (CPHI) had total debt of 3.57M, with a debt ratio of 0.23. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CPHI have?

    At the end of the period, China pharma holdings, inc. (CPHI) held Total Cash and Cash Equivalents of 267.63K, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CPHI go with three margins increasing?

    In the latest report, China pharma holdings, inc. (CPHI) did not achieve the “three margins increasing” benchmark, with a gross margin of -7.9%%, operating margin of -83.06%%, and net margin of -86.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CPHI's profit trajectory and future growth potential.

  • Is CPHI's EPS continuing to grow?

    According to the past four quarterly reports, China pharma holdings, inc. (CPHI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.17. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CPHI?

    China pharma holdings, inc. (CPHI)'s Free Cash Flow (FCF) for the period is -237.6K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 529.7% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.